Federal Register / Vol. 87, No. 113 / Monday, June 13, 2022 / Notices 35787 

for consumers, regulators, and 

Exchanges as well as to collect 

information to appropriately monitor 

and provide a process for a survey 

vendor to appeal HHS’ decision to not 

approve a QHP Enrollee Survey vendor 

application. Form Number: CMS–10520 

(OMB control number: 0938–1249); 

Frequency: Annually; Affected Public: 

Public sector (Individuals and 

Households); Private sector (Business or 

other for-profits and Not-for-profit 

institutions); Number of Respondents: 

314; Total Annual Responses: 314; Total 

Annual Hours: 384,014. (For policy 

questions regarding this collection 

contact Nidhi Singh Shah at 301–492– 

5110.) 

Dated: June 7, 2022 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2022–12651 Filed 6–10–22; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2022–D–0362] 

Blood Pressure and Pulse Donor 

Eligibility Requirements: Compliance 

Policy; Draft Guidance for Industry; 

Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability; 

correction. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

correcting a notice that appeared in the 

Federal Register of Tuesday, May 24, 

2022. The document announced the 

availability of a draft guidance entitled 

‘‘Blood Pressure and Pulse Donor 

Eligibility Requirements: Compliance 

Policy; Draft Guidance for Industry.’’ 

The draft guidance document was 

published with incorrect information of 

a comment period due date. This 

document corrects that error. 

FOR FURTHER INFORMATION CONTACT: 

Myrna Hanna, Center for Biologics 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 71, Rm. 7301, 

Silver Spring, MD 20993–0002, 240– 

402–7911. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of May 24, 2022 (87 FR 

31567), in FR Doc. 2022–11118, on page 

31567, the following correction is made: 

1. On page 3156, in the first column, 

the DATES caption is corrected to read: 

DATES: Submit either electronic or 

written comments on the draft guidance 

by July 25, 2022, to ensure that the 

Agency considers your comment on this 

draft guidance before it begins work on 

the final version of the guidance. 

Dated: June 3, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–12619 Filed 6–10–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2022–N–0686] 

Advisory Committee; Science Advisory 

Board to the National Center for 

Toxicological Research; Renewal 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; renewal of Federal 

advisory committee. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the renewal of the Science 

Advisory Board to the National Center 

for Toxicological Research (NCTR) by 

the Commissioner of Food and Drugs 

(the Commissioner). The Commissioner 

has determined that it is in the public 

interest to renew the Science Advisory 

Board to the National Center for 

Toxicological Research for an additional 

2 years beyond the charter expiration 

date. The new charter will be in effect 

until the June 2, 2024, expiration date. 

DATES: Authority for the Science 

Advisory Board to the National Center 

for Toxicological Research will expire 

on June 2, 2024, unless the 

Commissioner formally determines that 

renewal is in the public interest. 

FOR FURTHER INFORMATION CONTACT: 

Donna L. Mendrick, National Center for 

Toxicological Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 2208, Silver Spring, 

MD 20993–0002, 301–796–8892, 

Donna.Mendrick@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to 41 CFR 102–3.65 and approval by the 

Department of Health and Human 

Services pursuant and by the General 

Services Administration, FDA is 

announcing the renewal of the Science 

Advisory Board to the National Center 

for Toxicological Research (the 

Committee). The Committee is a 

discretionary Federal advisory 

committee established to provide advice 

to the Commissioner. The Committee 

advises the Commissioner or designee 

in discharging responsibilities as they 

relate to helping to ensure safe and 

effective drugs for human use and, as 

required, any other product for which 

FDA has regulatory responsibility. 

The Committee advises the Director, 

NCTR, in establishing, implementing, 

and evaluating research programs that 

assist the Commissioner in fulfilling his 

regulatory responsibilities. The 

Committee provides an extra-agency 

review in ensuring that the research 

programs at NCTR are scientifically 

sound and pertinent. 

The Committee shall consist of a core 

of nine voting members including the 

Chair. Members and the Chair are 

selected by the Commissioner or 

designee from among authorities 

knowledgeable in the fields of 

toxicological research. Members will be 

invited to serve for overlapping terms of 

up to 4 years. Almost all non-Federal 

members of this committee serve as 

Special Government Employees. Federal 

members will be appointed as Regular 

Government Employees or Ex-Officios. 

The core of voting members may 

include one technically qualified 

member, selected by the Commissioner 

or designee, who is identified with 

consumer interests and is recommended 

by either a consortium of consumeroriented organizations or other 

interested persons. 

The Commissioner or designee shall 

have the authority to select members of 

other scientific and technical FDA 

advisory committees (normally not to 

exceed 10 members) to serve 

temporarily as voting members and to 

designate consultants to serve 

temporarily as voting members when: 

(1) expertise is required that is not 

available among current voting standing 

members of the Committee (when 

additional voting members are added to 

the Committee to provide needed 

expertise, a quorum will be based on the 

combined total of regular and added 

members) or (2) to comprise a quorum 

when, because of unforeseen 

circumstances, a quorum is or will be 

lacking. Because of the size of the 

Committee and the variety in the types 

of issues that it will consider, FDA may, 

in connection with a particular 

committee meeting, specify a quorum 

that is less than a majority of the current 

voting members. The Agency’s 

regulations (21 CFR 14.22(d)) authorize 

a committee charter to specify quorum 

requirements. 

If functioning as a medical device 

panel, an additional non-voting 

representative member of consumer 

interests will be included in addition to 

the voting members. 


khammond on DSKJM1Z7X2PROD with NOTICES